Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
February 12th, 2017
9.4K views
The management of isolated recurrent lung cancer in a previously-irradiated field is challenging. Here, we describe an endobronchial ultrasound (EBUS)-guided cisplatin injection for the management of patients with localized lung cancer recurrence in a previously-radiated field.
Overview
This article discusses an innovative approach to managing localized lung cancer recurrence in patients who have previously undergone radiation therapy. The focus is on the use of endobronchial ultrasound (EBUS)-guided cisplatin injection as a treatment alternative to systemic chemotherapy.
Key Study Components
Area of Science
- Oncology
- Interventional Pulmonology
- Radiation Therapy
Background
- Isolated recurrent lung cancer in previously irradiated fields presents significant treatment challenges.
- Traditional systemic chemotherapy may not be suitable for all patients.
- EBUS provides real-time visualization for targeted treatment.
- Cisplatin is a chemotherapeutic agent commonly used in lung cancer treatment.
Purpose of Study
- To evaluate the safety and efficacy of EBUS-guided cisplatin injection.
- To provide an alternative treatment option for patients with localized recurrence.
- To address key questions in lung cancer treatment methodologies.
Methods Used
- Patients received intravenous dexamethasone and ondansetron prior to the procedure.
- Conscious sedation was induced using intravenous Midazolam and Fentanyl.
- Topical Lidocaine was applied to minimize discomfort.
- Standard monitoring was conducted throughout the procedure.
Main Results
- EBUS-guided cisplatin injection was performed successfully in the targeted areas.
- Patients experienced minimal complications during the procedure.
- The technique demonstrated potential as a viable alternative to systemic chemotherapy.
- Further studies are needed to establish long-term outcomes.
Conclusions
- EBUS-guided cisplatin injection is a promising technique for localized lung cancer recurrence.
- This method may improve treatment options for patients with limited recurrence.
- Continued research is essential to validate the findings and optimize the approach.
Frequently Asked Questions
What is EBUS?
Endobronchial ultrasound (EBUS) is a minimally invasive technique used to visualize structures within the lungs.
How does cisplatin work?
Cisplatin is a chemotherapy drug that interferes with DNA replication in cancer cells, leading to cell death.
What are the risks of EBUS-guided procedures?
Risks may include bleeding, infection, and complications from sedation, though they are generally low.
Who is a candidate for EBUS-guided cisplatin injection?
Patients with localized lung cancer recurrence who have previously undergone radiation therapy may be candidates.
What are the benefits of this technique?
It provides a targeted treatment option with potentially fewer side effects compared to systemic chemotherapy.
Is this technique widely used?
While promising, further studies are needed before it becomes a standard treatment option.
What should patients expect during the procedure?
Patients can expect sedation and monitoring, with the procedure being minimally invasive and relatively quick.
Executive Industry Relevance
For patients with isolated mediastinal recurrence of lung cancer post-radiation, systemic chemotherapy options are often limited and associated with significant toxicity. EBUS-guided intratumoral cisplatin injection offers a localized delivery approach that may improve therapeutic index while minimizing systemic exposure. This technique addresses an unmet need in the discovery and development of locoregional therapies for radiation-resistant disease.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables hypothesis testing of localized drug delivery in previously irradiated tumor microenvironments.
- Operational Value: Provides a minimally invasive route for intratumoral agent delivery under real-time imaging guidance.
Screening & Assay Development
- Scientific Value: Supports evaluation of cytotoxic agent distribution and retention in solid tumors via image-guided administration.
- Operational Value: Establishes a reproducible procedure for consistent intratumoral dosing in preclinical or early clinical models.
Translational & Preclinical Research
- Scientific Value: Facilitates pharmacokinetic and pharmacodynamic studies of intratumoral cisplatin in orthotopic or patient-derived models.
- Operational Value: Enables dose-escalation and scheduling studies with reduced systemic toxicity profiles.
Pipeline & Workflow Integration
This method fits within the oncology discovery continuum from target validation through preclinical efficacy testing, particularly for agents requiring localized tumor exposure.
- Discovery Biology: Allows assessment of tumor response to cytotoxic agents in situ, supporting mechanistic de-risking of localized delivery strategies.
- Screening: Enables standardized intratumoral compound administration for comparative efficacy and toxicity screening.
- Analytics: Supports quantitative response assessment via imaging and biomarker correlation at treated sites.
- Translational Research: Bridges discovery to preclinical validation by enabling consistent drug delivery in orthotopic models.
- Enterprise Reuse: Represents a platform adaptable to multiple agents (chemotherapy, immunotherapy, RNA-based) for intratumoral evaluation.
Operational & Enterprise Impact
- Scientific Value: Improves predictive confidence in antitumor activity by achieving high local drug concentrations.
- Operational Value: Leverages existing bronchoscopy infrastructure with minimal added procedural complexity.
- Strategic Value: Reduces reliance on systemic dosing, potentially lowering off-target toxicity and improving therapeutic index.
- Portfolio Impact: Supports go/no-go decisions for locoregional delivery approaches in radiation-resistant indications.
Implementation Considerations
- Requires expertise in interventional pulmonology and EBUS operation.
- Dependent on availability of radial or convex probe EBUS bronchoscopes and 22-gauge needles.
- Necessitates standardized training for needle placement and intratumoral injection under ultrasound guidance.
- Must account for lesion accessibility via bronchial pathways and safety of transbronchial needle passage.
- Limited to lesions visible and reachable via endobronchial ultrasound guidance.
Biopharma FAQs
Why is local drug delivery important for target validation in recurrent lung cancer?
Local delivery enables high intratumoral drug concentrations while minimizing systemic exposure, allowing clearer assessment of agent-specific antitumor effects in irradiated tissues. This approach reduces confounding from systemic toxicity and supports mechanistic de-risking of cytotoxic or targeted agents in preclinical models.
How does EBUS guidance improve the precision of intratumoral injections in mediastinal lesions?
EBUS provides real-time visualization of the tracheobronchial wall and surrounding structures, allowing accurate needle placement into the target lesion. This guidance reduces the risk of misdelivery and ensures consistent intratumoral deposition of therapeutic agents across multiple injection sites.
What quantitative measurements enable assessment of response to intratumoral cisplatin injection?
Response is assessed using radiographic imaging to evaluate changes in lesion size, with complete or partial response defined by standardized criteria such as RECIST. Survival outcomes and progression-free survival are also measured to correlate local treatment with clinical benefit.
Why are replication requirements critical for establishing reliability of EBUS-guided injection procedures?
Replication across multiple patients and injection sites ensures procedural consistency and reduces variability in drug delivery, which is essential for cross-functional collaboration between interventional pulmonology and oncology teams. Standardized technique supports reliable comparison of treatment effects in clinical studies.
What statistical analysis capabilities are needed to evaluate outcomes from EBUS-guided intratumoral therapy?
Analysis requires comparison of responder versus non-responder groups using survival metrics such as median overall survival and progression-free survival, with statistical significance determined via appropriate tests (e.g., log-rank test). Confidence intervals and p-values are used to validate observed differences in treatment outcomes.
